SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Phase II study of tight glycaemic control in COPD patients with exacerbations admitted to the acute medical unit.

Archer, JR; Misra, S; Simmgen, M; Jones, PW; Baker, EH (2011) Phase II study of tight glycaemic control in COPD patients with exacerbations admitted to the acute medical unit. BMJ Open, 1 (1). e000210. ISSN 2044-6055 https://doi.org/10.1136/bmjopen-2011-000210
SGUL Authors: Baker, Emma Harriet Jones, Paul Wyatt

[img]
Preview
PDF Published Version
Download (161kB) | Preview

Abstract

BACKGROUND: Hyperglycaemia is associated with poor outcomes from exacerbations of chronic obstructive pulmonary disease (COPD). Glycaemic control could improve outcomes by reducing infection, inflammation and myopathy. Most patients with COPD are managed on the acute medical unit (AMU) outside intensive care (ICU). OBJECTIVE: To determine the feasibility, safety and efficacy of tight glycaemic control in patients on an AMU. DESIGN: Prospective, non-randomised, phase II, single-arm study of tight glycaemic control in COPD patients with acute exacerbations and hyperglycaemia admitted to the AMU. Participants received intravenous, then subcutaneous, insulin to control blood glucose to 4.4-6.5 mmol/l. Tight glycaemic control was evaluated: feasibility, protocol adherence; acceptability, patient questionnaire; safety, frequency of hypoglycaemia (capillary blood glucose (CBG) <2.2 mmol/l and 2.2-3.3 mmol/l); efficacy, median CBG, fasting CBG, proportion of measurements/time in target range, glycaemic variability. RESULTS: were compared with 25 published ICU studies. Results 20 patients (10 females, age 71 ± 9 years; forced expiratory volume in 1 s: 41 ± 16% predicted) were recruited. Tight glycaemic control was feasible (78% CBG measurements and 89% of insulin-dose adjustments were adherent to protocol) and acceptable to patients. 0.2% CBG measurements were <2.2 mmol/l and 4.1% measurements 2.2-3.3 mmol/l. The study CBG and proportion of measurements/time in target range were similar to that of ICU studies, whereas the fasting CBG was lower, and the glycaemic variability was greater. CONCLUSIONS: Tight glycaemic control is feasible and has similar safety and efficacy on AMU to ICU. However, as more recent ICU studies have shown no benefit and possible harm from tight glycaemic control, alternative strategies for blood glucose control in COPD exacerbations should now be explored. Trial registration number ISRCTN: 42412334. http://Clinical.Trials.gov NCT00764556.

Item Type: Article
Additional Information: © 2011, Published by the BMJ Publishing Group Limited. This final article is available for use under the terms of the Creative Commons Attribution Non-Commercial 2.0 Licence.
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: BMJ Open
ISSN: 2044-6055
Dates:
DateEvent
23 July 2011Published
PubMed ID: 22021788
Web of Science ID: 22021788
Download EPMC Full text (PDF)
Download EPMC Full text (HTML)
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/1564
Publisher's version: https://doi.org/10.1136/bmjopen-2011-000210

Actions (login required)

Edit Item Edit Item